

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5475900

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	NOVARTIS AG	03/02/2015
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	ARRAY BIOPHARMA INC.	
<b>Street Address:</b>	3200 WALNUT ST.	
<b>City:</b>	BOULDER	
<b>State/Country:</b>	COLORADO	
<b>Postal Code:</b>	80301	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	15818264
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(877)769-7945	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(617) 542-5070	
<b>Email:</b>	apsi@fr.com	
<b>Correspondent Name:</b>	JOHN T. KENDALL	
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.	
<b>Address Line 2:</b>	P.O.BOX 1022	
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022	
<b>ATTORNEY DOCKET NUMBER:</b>	41357-0007008	
<b>NAME OF SUBMITTER:</b>	JILL A. WRIGHT	
<b>SIGNATURE:</b>	/Jill A. Wright/	
<b>DATE SIGNED:</b>	04/16/2019	
<b>Total Attachments: 8</b>		
source=Novartis AG to Array#page1.tif		
source=Novartis AG to Array#page2.tif		
source=Novartis AG to Array#page3.tif		
source=Novartis AG to Array#page4.tif		
source=Novartis AG to Array#page5.tif		

source=Novartis AG to Array#page6.tif  
source=Novartis AG to Array#page7.tif  
source=Novartis AG to Array#page8.tif

**NERVIANO PATENT ASSIGNMENT AGREEMENT**

This NERVIANO PATENT ASSIGNMENT AGREEMENT, dated March 18, 2015, and effective as of March 2, 2015, is made by and between Novartis AG, a Swiss corporation (“**Assignor**”), and Array BioPharma Inc., a Delaware corporation (“**Assignee**”). Capitalized terms used but not defined herein will have the meanings given to them in the Asset Transfer Agreement, dated January 19, 2015 (the “**Agreement**”), by and between Assignor and Assignee.

WHEREAS, Assignor is the owner of the entire right, title and interest in, to and under the patents and/or patent applications set forth on Schedule A attached hereto (the “**Transferred Patents**”) and has the unrestricted right to sell, assign and transfer such patents and/or patent applications; and

WHEREAS, pursuant to the terms of the Agreement, Assignor has agreed, among other things, to transfer to Assignee said patents and/or patent applications.

NOW THEREFORE, for good and valuable consideration of the payment of the amounts set forth in the Agreement, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

Section 1. Assignor hereby conveys, sells, assigns, and transfers to Assignee, and Assignee hereby accepts, Assignor’s entire right, title and interest in, to and under the Transferred Patents, including all issuances, divisions, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, and extensions and all rights of any kind accruing under any of the foregoing provided by Applicable Laws, by international treaties and conventions and otherwise throughout the world, and any and all accounts, contract rights, warranties, litigation claims and rights, including the right to sue for and collect upon all claims for profits and damages as a result of past infringement, if any, related to any of the foregoing, in each case whether now existing or hereafter acquired or created, whether owned, leased or licensed beneficially or of record and whether owned, leased or licensed individually, jointly or otherwise, together with the products and proceeds thereof (including license royalties and the proceeds of infringement suits), all payments and other distributions with respect thereto (all of the foregoing herein collectively referred to as the “**Patent Rights**”).

Section 2. Assignor hereby authorizes the Commissioners for Patents and Trademarks of the U.S. Patent and Trademark Office and other empowered officials of relevant intellectual property offices and other governmental or regulatory authorities in each jurisdiction other than the United States, to record the transfer to Assignee of all of Assignor’s rights, title and interests in, to and under the Patent Rights, and to issue all future registrations and other rights relating to such Patent Rights to Assignee.

Section 3. Assignor hereby covenants that, from time to time after the delivery of this instrument, at Assignee’s request and without further consideration, Assignor will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further acts, deeds, conveyances, transfers, assignments, powers of attorney and assurances

as reasonably may be required more effectively to convey and transfer to Assignee, and put Assignee in possession of, any of the Patent Rights.



Section 4. In the event of any conflict between this Patent Assignment Agreement and the Agreement, the provisions in the Agreement shall control. Nothing herein is intended to alter, modify, expand or diminish the terms set forth in the Agreement.

Section 5. This Patent Assignment Agreement is executed by, and will be binding upon, Assignee and Assignor and their respective successors and assigns for the uses and purposes set forth herein, effective immediately upon the Effective Date.

*[signature page follows]*

IN WITNESS WHEREOF, the parties hereto have caused this Patent Assignment Agreement to be signed by their respective representatives thereunto duly authorized, all as of the date first written above.

ARRAY BIOPHARMA, INC.

By:   
Name: \_\_\_\_\_  
Title:  John Moore  
General Counsel

NOVARTIS AG

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_


By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_


IN WITNESS WHEREOF, the parties hereto have caused this Patent Assignment Agreement to be signed by their respective representatives thereunto duly authorized, all as of the date first written above.

ARRAY BIOPHARMA INC.

By: \_\_\_\_\_  
Name:  
Title:

NOVARTIS AG

By:  \_\_\_\_\_  
Name: Felix R. Ehrat  
Title: Group General Counsel

By:  \_\_\_\_\_  
Name: Harry Kinsch  
Title: Chief Financial Officer

# SCHEDULE A

## Patents

Ctry	Filing Date	Filing Number	Grant Number	Grant Date	Expiry
AE	27 Aug 2010	P202/12			27 Aug 2030
AL	27 Aug 2010	10748211.9	AL-P-2014-222	28 May 2014	27 Aug 2030
AR	26 Aug 2010	P100103123			26 Aug 2030
AT	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
AU	27 Aug 2010	2010286569	2010286569	23 Jan 2014	27 Aug 2030
BA	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
BB	27 Aug 2010	2001/1667			27 Aug 2030
BE	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
BG	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
BO	26 Aug 2010	SP210263			26 Aug 2030
BR	27 Aug 2010	112012004453.2			27 Aug 2030
BS	24 Aug 2010	2272	2272	06 May 2014	24 Aug 2026
BZ	27 Aug 2010	717.12			27 Aug 2030
CA	27 Aug 2010	2771775			27 Aug 2030
CH	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
CL	27 Aug 2010	00340/2012			27 Aug 2030
CN	27 Aug 2010	201080038197.8	201080038197.8	26 Feb 2014	27 Aug 2030
CN	28 Jan 2014	201410040923.X			27 Aug 2030
CO	27 Aug 2010	12032570		29 Apr 2014	27 Aug 2030
CR	27 Aug 2010	2012-0102			27 Aug 2030
CU	27 Aug 2010	2012-0034			27 Aug 2030
CY	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
CZ	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
DE	27 Aug 2010	10748211.9	602010016362.8	28 May 2014	27 Aug 2030
DK	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
DO	27 Aug 2010	P2012-0051			27 Aug 2030
DZ	27 Aug 2010	120182			27 Aug 2030
EA	27 Aug 2010	201200373			27 Aug 2030
EC	27 Aug 2010	SP-12-11700			27 Aug 2030
EE	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030

Ctry	Filing Date	Filing Number	Grant Number	Grant Date	Expiry
EG	27 Aug 2010	292/2012			27 Aug 2030
EP	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
EP	28 Jan 2014	14152945.3			27 Aug 2030
ES	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
FI	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
FR	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
GB	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
GC	25 Aug 2010	2010-16548			25 Aug 2030
GE	27 Aug 2010	12645/01	P6102	21 Jul 2014	27 Aug 2030
GR	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
GT	27 Aug 2010	A-2012-00053			27 Aug 2030
HK					
HK	15 Aug 2012	12108012.3			27 Aug 2030
HK	20 May 2014	14104691.8			27 Aug 2030
HN	27 Aug 2010	2012/441			27 Aug 2030
HR	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
HU	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
ID	27 Aug 2010	W00201201145		21 Aug 2014	27 Aug 2030
IE	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
IL	27 Aug 2010	218084			27 Aug 2030
IN	27 Aug 2010	2469/DELNP/2012			27 Aug 2030
IQ	23 Aug 2010	251/2010	3864	10 Apr 2014	14 Mar 2031
IR	16 Aug 2010	389050928			16 Aug 2030
IS	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
IT	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
JM	25 Aug 2010	18/1/5105			
JO	26 Aug 2010	297/2010			26 Aug 2030
JP	27 Aug 2010	2012-527014	5475888	14 Feb 2014	27 Aug 2030
JP	06 Feb 2014	2014-021339			27 Aug 2030
KR	27 Aug 2010	2012-7007860	1413392	23 Jun 2014	27 Aug 2030
LB	20 Aug 2010	9116	9116	02 Jul 2012	20 Aug 2030
LK	27 Aug 2010	LK/P/1/16609			28 Aug 2029
LT	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
LU	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030



Ctry	Filing Date	Filing Number	Grant Number	Grant Date	Expiry
LV	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
LY	27 Aug 2010	4397/2012			27 Aug 2025
MA	27 Aug 2010	PV34716	33604	01 Sep 2012	27 Aug 2030
MC	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
MK	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
MO	09 Apr 2014	J/1384	J/1384	16 Jul 2014	27 Aug 2030
MT	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
MX	27 Aug 2010	MX/A/12/002546	321039	12 Jun 2014	27 Aug 2030
MY	27 Aug 2010	PI 2012000611			27 Aug 2030
NI	27 Aug 2010	2012-000029			27 Aug 2030
NL	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
NO	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
NZ	27 Aug 2010	598924	598924	30 Oct 2013	27 Aug 2030
PA	27 Aug 2010	88907-01	88907-01	12 Jan 2012	27 Aug 2030
PE	27 Aug 2010	000268-2012/DIN			27 Aug 2030
PH	27 Aug 2010	1-2012-500380			27 Aug 2030
PK	25 Aug 2010	740/2010			28 Aug 2029
PL	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
PT	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
PY	27 Aug 2010	35100/2010			27 Aug 2030
RO	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
RS	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
SE	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
SG	27 Aug 2010	201200930.4	178351	04 Sep 2014	27 Aug 2030
SG	28 Aug 2014	1020145311T			27 Aug 2030
SI	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
SK	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
SM	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
SV	27 Aug 2010	2012004151			27 Aug 2030
SY	27 Aug 2010	2012030055			27 Aug 2030
TH	27 Aug 2010	1201000794			27 Aug 2030
TN	27 Aug 2010	TN20120081			27 Aug 2030
TR	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030
TT	27 Aug 2010	TT/A/2012/00034			27 Aug 2030

Ctry	Filing Date	Filing Number	Grant Number	Grant Date	Expiry
TW	27 Aug 2010	099128957			27 Aug 2030
UA	27 Aug 2010	A201203042			27 Aug 2030
US	28 Jun 2013	13/931111			27 Aug 2030
US	27 Aug 2010	12/870130	8501758	06 Aug 2013	04 Mar 2031
US	28 Aug 2009	61/238073			28 Aug 2010
US	11 Mar 2010	61/313039			11 Mar 2011
UY	27 Aug 2010	32.860			27 Aug 2030
UZ	27 Aug 2010	IAP2012-0114			27 Aug 2030
VE	26 Aug 2010	1335-10			
VN	27 Aug 2010	1-2012-00838			27 Aug 2030
WO	27 Aug 2010	PCT/US2010/046930			
ZA	27 Aug 2010	2012/02020	2012/02020	27 Dec 2012	27 Aug 2030
KS	27 Aug 2010	135/2010			27 Aug 2030
ME	27 Aug 2010	10748211.9	EP2470526	28 May 2014	27 Aug 2030

PATENT

REEL: 048892 FRAME: 0474

RECORDED: 04/16/2019